Business Wire4d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
GlobalData on MSN2d
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
FierceBiotech3d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
The American Journal of Managed Care3d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
medtechdive1d
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Morningstar4d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
“Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with ...
MassDevice2d
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...